|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Ovarian cancer standard of care: are there real alternatives?显示文摘Ovarian cancer remains a major issue for gynecological oncologists, and most patients are diagnosed when the disease is already advanced with a poor chance of survival. Debulking surgery followed by platinum-taxane chemotherapy is the current standard of care, but based on several different strategies currently under evaluation, some encouraging data have been published in the last 4 to 5 years. This review provides a state-of-the-art overview of the available alternatives to conventional treatment and the most promising new combinations. For example, neoadjuvant chemotherapy does not seem to be inferior to primary debulking. Despite its outcome improvements, intraperitoneal chemotherapy struggles for acceptance due to the heavy toxicity. Dose-dense chemotherapy, after showing an impressive efficacy in Asian populations, has not produced equal results in a European cohort, and the results of alternative platinum doublets are not superior to those of carboplatin and paclitaxel. In this setting, adherence to a maintenance therapy after first-line treatment and multiple(primarily antiangiogenic) agents appears to be effective. Although many questions, including the duration of maintenance treatment and the use of bevacizumab beyond progression, remain unanswered, new biologic agents, such as poly(ADP-ribose) polymerase(PARP) inhibitors, nintedanib, and mitogen-activated protein/extracellular signal-regulated kinase(MEK) inhibitors, have emerged as potential therapeutic options in the very near future. Based on the multiplicity of available strategies, the histological and molecular features of the tumor, in addition to patient's clinical condition and disease state, continue to gain importance in guiding treatment choices. | Chiara Della Pepa Giuseppe Tonini Carmela Pisano Marilena Di Napoli Sabrina Chiara Cecere Rosa Tambaro Gaetano Facchini Sando Pignata | 2015 | Chinese Journal of Cancer2015，34，1： | 5 |
| 2 | Pancreatic cancer in 2021:What you need to know to win显示文摘Pancreatic cancer is one of the solid tumors with the worst prognosis.Five-year survival rate is less than 10%.Surgical resection is the only potentially curative treatment,but the tumor is often diagnosed at an advanced stage of the disease and surgery could be performed in a very limited number of patients.Moreover,surgery is still associated with high post-operative morbidity,while other therapies still offer very disappointing results.This article reviews every aspect of pancreatic cancer,focusing on the elements that can improve prognosis.It was written with the aim of describing everything you need to know in 2021 in order to face this difficult challenge. | Valeria Tonini Manuel Zanni | 2021 | World Journal of Gastroenterology2021，27，35： | 4 |
| 3 | Headache, anxiety and depressive disorders: the HADAS study显示文摘 | Ettore Beghi Gennaro Bussone Domenico D’Amico Pietro Cortelli Sabina Cevoli Gian Camillo Manzoni Paola Torelli Maria Clara Tonini Giovanni Allais Roberto Simone Florindo D’Onofrio Sergio Genco Franca Moschiano Massimiliano Beghi Sara Salvi | 2010 | The Journal of Headache and Pain2010，，2： | 3 |
| 4 | Target Therapies in Pancreatic Carcinoma显示文摘 | Nicola Silvestris Antonio Gnoni Anna Elisabetta Brunetti Leonardo Vincenti Daniele Santini Giuseppe Tonini Francesca Merchionne Evaristo Maiello Vito Lorusso Patrizia Nardulli Amalia Azzariti Michele Reni | 2014 | Current Medicinal Chemistry2014，，8： | 2 |
| 5 | Subagging for credit scoring models 显示文摘 | GIUSEPPE PALEOLOGO ANDRe ELISSEEFF GIANLUCA AN- TONINI | 2010 | European Jour- nal of Operational Research2010，，201： | 1 |
| 6 | Short-term longitudinal evaluation of cerebral blood flow in mild Alzheimer's disease显示文摘 | Tonini G Shanks MF Venneri A | 2003 | Neurol Sci2003，24，： | 1 |
| 7 | Biological interaction between anti epidermal growth factor receptor agent eetuximab and magnesium 显示文摘 | Vincenzi B Santini D Tonini G | 2008 | Expert Opin Pharmacother2008，9，8： | 1 |
| 8 | Role of nitric oxide-and vasoactive intestinal polypeptide-containing neurones in human gastric fundus strip relaxations显示文摘 | TONINI M DE GIORGIO R PONTI F | 2000 | Br J Pharmacol2000，129，1： | 1 |
| 9 | Alloys at low nickel-release:Pd-Ni coatings on copper显示文摘 | Moretti G Guidi F Tonini R | 2001 | Plating and Surface Finishing2001，88，4： | 1 |
| 10 | Effects of esomeprazole on glutathione levels and mitochondrial oxidative phosphorylation in the gastric mucosa of rats treated with indomethacin显示文摘 | O. Pastoris M. Verri F. Boschi O. Kastsiuchenka B. Balestra F. Pace M. Tonini G. Natale | 2008 | Naunyn-Schmiedeberg’s Archives of Pharmacology2008，，4： | 1 |
| 11 | Irritable bowel syndrome:new agents targeting serotonin receptor subtypes显示文摘 | DE PONTI F TONINI M | 2001 | Drugs2001，61，： | 1 |
| 12 | Ezh2 reduces the ability of HDAC1-dependent pRb2/p130 transcriptional repression of cyclin A显示文摘 | Tonini T Bagella L DAndrilli G | 2004 | Oncogene2004，23，28： | 1 |
| 13 | Oxaliplatin may induce cytokine-release syndrome in colorectal cancer patients显示文摘 | Tonini G Santini D Vincenzi B | 2002 | J Biol Regul Homeost Agents2002，16，2： | 1 |
| 14 | Molecular basis of angiogenesis and cancer显示文摘 | Tonini T Rossi F Clandio PP | 2003 | Oncogene2003，22，42： | 1 |
| 15 | Cyclooxygenase-2 over- expression is associated with a poor outcome in resected ampulla- ry cancer patients 显示文摘 | Santini D Vincenzi B Tonini G | 2005 | Clin Cancer Res2005，11，10： | 1 |
| 16 | Prolonged survival after extracranial metastasectomy from synchronous resectable lung canccr显示文摘 | Ambrogi V Tonini G Mineo TC | 2001 | Ann Surg Oncol2001，8，8： | 1 |
| 17 | Impact of anastomotic leakage on long-term prognosis after colorectal cancer surgery显示文摘Colorectal cancer(CRC)is one of the most common malignancies in the world.Despite significant improvements in surgical technique,postoperative complications still occur in a fair percentage of patients undergoing colorectal surgery.The most feared complication is anastomotic leakage.It negatively affects shortterm prognosis,with increased post-operative morbidity and mortality,higher hospitalization time and costs.Moreover,it may require further surgery with the creation of a permanent or temporary stoma.While there is no doubt about the negative impact of anastomotic dehiscence on the short-term prognosis of patients operated on for CRC,still under discussion is its impact on the long-term prognosis.Some authors have described an association between leakage and reduced overall survival,disease-free survival,and increased recurrence,while other Authors have found no real impact of dehiscence on long term prognosis.The purpose of this paper is to review all the literature about the impact of anastomotic dehiscence on long-term prognosis after CRC surgery.The main risk factors of leakage and early detection markers are also summarized. | Valeria Tonini Manuel Zanni | 2023 | World Journal of Gastrointestinal Surgery2023，15，5： | 1 |
| 18 | Steady-State Response Audiometry in a Group of Patients with Steeply Sloping Sensorineural Hearing Loss显示文摘 | Ballay Charles MD Tonini | 2005 | Laryngoscope2005，115，7： | 1 |
| 19 | Oxaliplatin may induce cytokine-release syndrome in colorectal cancer patients 显示文摘 | Tonini G Santini D Vincenzi B | 2002 | J Biol Regul Homeost Agents2002，16，2： | 1 |
| 20 | Oxaliplatinmay induce cytokine-release syndrome in colorectal cancer patients显示文摘 | Tonini G Santini D Vincenzi B | 2002 | J Biol Pegul Homeost Agents2002，16，： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员